In Person Seminar: Engineering Post-translational Regulation of Ion Channels
Henry M. Colecraft, Ph.D.
John C. Dalton Professor
Department of Physiology and Cellular Biophysics
Columbia University Irving Medical Center
Pioneers in Biomedical Research Seminar: Engineering Post-translational Regulation of Ion Channels
Date: April 21, 2023
Time: 11 a.m. - 12 p.m.
About this Seminar
Modulation of ion channel expression and activity is a critical mechanism to tune physiology and attack diseases, and also an important avenue for developing novel therapeutics. Dr. Colecraft will discuss our work focused on engineering new ways to selectively modulate the expression and function of distinct ion channels that exploits targeted induced proximity of enzymes including E3 ubiquitin ligases, deubiquitinases, and kinases. The applications of this approach to develop novel therapeutics will be emphasized.
Additional Details
This is a free event hosted by the Fralin Biomedical Research Institute and co-sponsored by the institute's Center for Vascular and Heart Research. The Pioneers in Biomedical Research Seminar Series, which runs annually from September to May, has featured leading biomedical researchers from throughout the country since the program began in 2012. The lectures are also open to all members of the Virginia Tech community including graduate students, undergraduates, faculty, and staff, as well as the public.
You May Also Be Interested In...
-
Home ItemPathways and Regulation of Cardiac Nav1.5 Channel Trafficking in Adult Myocytes , home
May 30, 2025, 11:00 a.m. | Gea-Ny Tseng, Ph.D., Professor, Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home ItemTargeting Acquired Dependencies During Tumor Evolution , home
June 6, 2025, 11:00 a.m. | Kris Wood, Ph.D., Associate Professor, Department of Pharmacology and Cancer Biology, Duke University School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – D.C.